For many patients with kidney cancer, surgery represents the most important step toward a cure. However, even after a successful nephrectomy, the risk of recurrence remains a significant concern, particularly among patients with high-risk disease.
Now, a newly approved treatment combination may offer additional protection against cancer returning.
In June 2026, the U.S. Food and Drug Administration (FDA) approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant therapy for adults with clear cell renal cell carcinoma (ccRCC) at intermediate-high or high risk of recurrence following surgery.
This approval represents an important advance in kidney cancer care and introduces the first approved combination of a PD-1 inhibitor and a HIF-2α inhibitor in this setting.
Why Is Recurrence a Challenge in Kidney Cancer?
Renal cell carcinoma is the most common type of kidney cancer, and clear cell renal cell carcinoma accounts for approximately 75–80% of all cases.
Although surgery can successfully remove the primary tumor, microscopic cancer cells may remain undetected elsewhere in the body. Over time, these cells can grow and lead to disease recurrence.
Patients with large tumors, lymph node involvement, or tumors that had previously spread and were surgically removed face a particularly high risk of relapse.
Historically, physicians had limited options to reduce this risk beyond close surveillance.
The landscape began to change in 2021 with the approval of adjuvant pembrolizumab following the KEYNOTE-564 trial, which demonstrated improved disease-free survival after nephrectomy in patients at increased risk of recurrence.
Researchers have now taken the next step by combining pembrolizumab with a drug that targets a completely different pathway involved in kidney cancer progression.
Understanding Pembrolizumab: Releasing the Brakes on the Immune System
Pembrolizumab belongs to a class of immunotherapy drugs known as immune checkpoint inhibitors.
Under normal circumstances, cancer cells can evade immune detection by activating PD-1, a molecular “brake” found on T cells. When PD-1 is engaged, immune cells become less effective at attacking tumors.
Pembrolizumab blocks this interaction, helping the immune system recognize and destroy cancer cells more effectively.
This strategy has transformed the treatment of multiple cancers, including melanoma, lung cancer, bladder cancer, and kidney cancer.
However, not all patients respond equally, and researchers have continued searching for ways to improve outcomes.
What Makes Belzutifan Different?
Belzutifan targets a pathway that plays a particularly important role in clear cell renal cell carcinoma.
Most ccRCC tumors contain alterations involving the Von Hippel-Lindau (VHL) gene. Under normal conditions, VHL helps regulate the body’s response to oxygen levels by controlling proteins known as hypoxia-inducible factors (HIFs).
When VHL function is lost, HIF proteins—especially HIF-2α—accumulate abnormally and activate genes that promote tumor growth, angiogenesis, metabolism, and cell survival.
Belzutifan is an oral therapy specifically designed to inhibit HIF-2α. By targeting this central driver of kidney cancer biology, the drug interferes with processes that tumors rely on to continue growing.
Previous studies in advanced renal cell carcinoma demonstrated meaningful anti-tumor activity and established belzutifan as a promising therapeutic option.
The Science Behind the Combination
The rationale for combining pembrolizumab and belzutifan is compelling. Pembrolizumab activates anti-tumor immune responses, while belzutifan directly blocks a critical molecular pathway driving kidney cancer progression.
Together, they attack the disease through two complementary mechanisms.
Researchers hypothesized that inhibiting HIF-2α could not only suppress tumor growth directly but also create a tumor microenvironment more favorable for immune attack.
This concept led to the development of the Phase III LITESPARK-022 trial, which enrolled more than 1,800 patients with clear cell renal cell carcinoma who had undergone nephrectomy and remained at elevated risk of recurrence.
Participants received:
- Pembrolizumab plus belzutifan
- Pembrolizumab plus placebo
The combination reduced the risk of recurrence, metastasis, or death by approximately 28% compared with pembrolizumab alone, demonstrating a statistically significant improvement in disease-free survival.
Importantly, this was the first global Phase III study to demonstrate an improvement over pembrolizumab monotherapy in the adjuvant treatment of clear cell renal cell carcinoma.
For many experts, these findings represent one of the most significant advances in kidney cancer management since the introduction of adjuvant immunotherapy.
Why Does Disease-Free Survival Matter?
Disease-free survival (DFS) measures the length of time patients remain free of detectable cancer following treatment.
In high-risk kidney cancer, recurrence often precedes the development of metastatic disease, which can be more difficult to control.
Reducing the likelihood of recurrence may translate into long-term benefits, improved quality of life, and potentially improved overall survival as additional follow-up data become available.
Although overall survival data from LITESPARK-022 are not yet mature, preventing recurrence remains a meaningful clinical goal for both patients and physicians.
Figure 1. Following surgery, residual tumor cells may persist; pembrolizumab enhances anti-tumor immune activity while belzutifan inhibits HIF-2α signaling, collectively reducing proliferation, angiogenesis, and recurrence risk.
Who May Benefit From This New Treatment?
The FDA approval applies to adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence following:
- Nephrectomy alone
- Nephrectomy with surgical resection of metastatic lesions
These are patients who have already undergone surgery but remain at substantial risk for the cancer returning in the future.
Not every patient with kidney cancer will require adjuvant treatment. Therapeutic decisions continue to depend on tumor stage, pathology findings, overall health status, and individual risk factors.
Researchers continue to evaluate combinations involving HIF-2α inhibition, immunotherapy, and novel targeted therapies across different stages of kidney cancer.
The goal is not only to treat advanced disease but also to prevent recurrence before it occurs.
Conclusion
The approval of belzutifan plus pembrolizumab highlights an important trend in oncology: combining immunotherapy with targeted therapies based on tumor biology.
Rather than relying on a single mechanism, modern cancer treatment increasingly employs complementary approaches that attack tumors from multiple directions simultaneously.
This article is intended solely for educational and informational purposes. It is not intended to provide medical advice, diagnosis, or treatment recommendations. Readers should consult qualified healthcare professionals regarding any medical concerns or decisions related to their health.
Main reference:
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. (2026, junio 12). U.S. Food and Drug Administration; FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma
Other reference:
Choueiri, T. K., Motzer, R. J., Karam, J. A., Ye, D., He, Z., Caglevic, C., Yip, W., Suárez, C., Ferguson, T., Chang, W. Y. H., Rojas, C., Iacovelli, R., Ürün, Y., Verzoni, E., Vázquez Limón, J. C., Porta, C., Liu, H., Sharma, M., Burgents, J. E., & Powles, T. (2026). Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 44(7_suppl). https://doi.org/10.1200/jco.2026.44.7_suppl.lba418
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y. H., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., Thiery-Vuillemin, A., Gross-Goupil, M., Mahave, M., Haas, N. B., Sawrycki, P., Gurney, H., Chevreau, C., Melichar, B., Kopyltsov, E., Alva, A., … KEYNOTE-564 Investigators (2021). Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. The New England journal of medicine, 385(8), 683–694. https://doi.org/10.1056/NEJMoa2106391
